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Macrolides Are Associated with a Better Survival
Rate in Patients Hospitalized with Community-Acquired
But Not Healthcare-Associated Pneumonia
Colleen McEvoy,1 Scott T. Micek,2 Richard M. Reichley,3 Jason Kan,2 Alex Hoban,1
Justin Hoffmann,4 Andrew F. Shorr,5 and Marin H. Kollef1
Abstract
Background: Macrolide-based treatment has been associated with survival benefit in patients hospitalized with
community-acquired pneumonia (CAP). However, the influence of macrolide therapy in all patients hospital-
ized with pneumonia, including healthcare-associated pneumonia (HCAP), is unclear.
Methods: Analysis of a retrospective single-center cohort.
Results: Community-acquired pneumonia was present in 220 (22.5%) of all patients with pneumonia admitted
through the emergency department of Barnes-Jewish Hospital, and HCAP was present in 757. Macrolide-based
treatment was administered to 411 patients (42.1%). These patients were more likely to have CAP than were
patients not receiving macrolide-based therapy (35.3% vs. 13.3%; p < 0.001) and had lower scores on the
CURB-65 tool, a measure of the severity of illness (2.4– 1.5 vs. 3.1– 1.3; p< 0.001). Patients receiving
macrolides also had a lower hospital mortality rate in univariable analysis (12.7% vs. 27.2%; p < 0.001). A
propensity score analysis showed that macrolide-based treatment was associated with a lower in-hospital
mortality rate (adjusted odds ratio [AOR] 0.67; 95% confidence interval [CI] 0.54–0.81; p= 0.043). Separate
propensity score analyses of patients with CAP (AOR 0.20; 95% CI 0.11–0.34; p= 0.003) and HCAP (AOR
0.81; 95% CI 0.65–1.01; p= 0.337) produced discordant findings.
Conclusions: Macrolide-based treatment was associated with better survival in patients hospitalized with
pneumonia. The survival advantage appeared predominantly among patients with CAP.
Pneumonia is one of the leading causes of death andthe leading cause of hospitalization attributable to an
infectious disease [1,2]. For patients hospitalized with
pneumonia, 30-d mortality rates are as high as 23%, and
annual expenditures in the United States for the treatment of
these infections are $8–$10 billion [1,3]. Patients hospital-
ized with pneumonia generally are categorized as having
either community-acquired pneumonia (CAP) or healthcare-
associated pneumonia (HCAP) on the basis of their exposure
to the healthcare system.
Previous studies have suggested that morbidity and mor-
tality rates are reduced with macrolide-based regimens in
patients with CAP [4–7]. We are unaware of any analyses
examining the impact of macrolide-based treatment in pa-
tients hospitalized with pneumonia that included both pa-
tients with CAP and those with HCAP. The increasing
population of patients hospitalized with HCAP highlights the
importance of determining the clinical significance or lack
thereof of macrolide therapy for this important subgroup of
patients [8]. Therefore, we conducted a study to determine
whether macrolide-based treatment is associated with a sur-
vival benefit in a consecutive group of patients hospitalized
with pneumonia of either type.
Patients and Methods
Study Design
A retrospective cohort analysis was performed of all pa-
tients admitted through the emergency department to Barnes-
Jewish Hospital (1,250 beds) with a diagnosis of pneumonia
1Division of Pulmonary and Critical Care Medicine, Washington University School of Medicine, St. Louis, Missouri.
2Department of Pharmacy and 3Center for Clinical Excellence, Barnes-Jewish Hospital, St. Louis, Missouri.
4St. Louis College of Pharmacy, St. Louis, Missouri.
5Pulmonary and Critical Care Medicine, Washington Hospital Center, Washington, DC.
SURGICAL INFECTIONS
Volume 15, Number 3, 2014
ª Mary Ann Liebert, Inc.
DOI: 10.1089/sur.2013.076
283
over a 12-mo period ( January–December 2010). We ex-
cluded patients transferred from other hospitals directly to the
wards or to the intensive care unit (ICU). This study was
approved by the Washington University School of Medicine
Human Studies Committee.
Data Source
One of the investigators (RMR) identified potential study
patients by the presence of either a primary or secondary
International Classification of Diseases-9-CM code indica-
tive of pneumonia. Patients with pneumonia were further
identified using the definitions described below. The initial
study database was constructed by merging patient-specific
data from the automated hospital medical records and mi-
crobiology and pharmacy databases of the hospital.
Definitions
Diagnosis of pneumonia necessitated both signs and
symptoms of infection (i.e., elevated white blood cell count
or > 10% band forms; fever or hypothermia; chest radiograph
revealing an infiltrate[s]). One investigator (MHK), blinded
to the determination of pneumonia, reviewed the chest im-
ages. The diagnosis of a bacterial infection required a positive
culture of blood, pleural fluid, sputum, or the lower airways.
We also considered a positive urinary antigen test for either
Streptococcus pneumoniae or Legionella spp. as documen-
tation of a bacterial infection.
A HCAP was defined as pneumonia in a patient admitted
to the hospital with one of the following risk factors: (1)
Residence in a nursing home, rehabilitation hospital, or other
long-term nursing facility; (2) hospitalization within the
immediately preceding 12 mo; or (3) receiving outpatient
hemodialysis, peritoneal dialysis, wound care, or infusion
therapy necessitating regular visits to a hospital-based clinic.
We also determined the presence of an immunocompromised
state, defined as being seropositive for the human immuno-
deficiency virus (HIV), active malignancy undergoing che-
motherapy, or treatment with immunosuppressants (i.e.,
10mg of prednisone or equivalent or a similar agent daily for
at least 30 d).
Antimicrobial treatment was classified as being appropri-
ate if the initially prescribed antibiotic regimen was active
against the identified pathogen, as judged by in vitro sus-
ceptibility testing. Patients with pneumonia attributed to
Legionella spp. were defined as receiving appropriate treat-
ment if their initial antibiotic regimen included a macrolide
(e.g., azithromycin) or respiratory quinolone (e.g., moxi-
floxacin). Appropriate antimicrobial treatment had to be
prescribed within 24 h of hospital admission.
Statistics
Discrete variables were expressed as counts (percentage)
and continuous variables as mean – standard deviation (SD)
or medians with the 25th–75th percentile interquartile range
(IQR). The X2 test or Fisher exact test was used for cate-
gorical variables and the Student t-test or the Mann–Whitney
U test for continuous variables as appropriate. Multivariable
stepwise logistic regression analysis was used to assess the
impact of explanatory variables on outcome (in-hospital
death). To avoid spurious associations, only variables with a
relation in univariable analysis (p £ 0.1) or a potential plau-
sible relation to the outcome were entered in the logistic
regression models.
In addition, the effectiveness of macrolide therapy on the
hospital mortality rate was estimated further using propensity
scores. These scores were estimated by fitting a logistic re-
gression model. The covariates included in the propensity
score model were those measured previous to macrolide
treatment having a potential impact on outcome: Age, CURB-
65 score, Charlson comorbidity score, gender, chronic ob-
structive pulmonary disease (COPD), congestive heart failure,
chronic renal disease, hematologic or malignant disease, solid
tumor, diabetes mellitus, immunosuppression including the
presence of human immunodeficiency virus (HIV), dementia,
recent hospitalization, admission from a nursing home, and
antibiotic treatment within the previous 90 d. Propensity score
quintiles were derived, and boxplots of the estimated pro-
pensity scores for macrolide-treated and -untreated patients
within each quintile of the propensity scores were plotted to
assess the validity of the analysis. Finally, we fitted a logistic
model for in-hospital death, including as covariates the pro-
pensity score andmacrolide treatment. Results are presented as
adjusted odds ratios (AORs) and 95% confidence intervals
(CIs). Additionally, we repeated these analyses for the sub-
groups of patients with CAP and HCAP. Finally, we per-
formed a logistic regression analysis for the subgroup of
patients receiving macrolide therapy to determine the factors
associated with survival. For all analyses, p values< 0.05 were
considered significant. We used SPSS for Windows 19.0
(SPSS, Chicago, IL) for all analyses.
Results
Nine hundred seventy-seven consecutive patients with
pneumonia admitted to Barnes-Jewish Hospital in 2010 were
included in the study. The mean age of the patients was
60.5 – 16.9 y (range 17–102 y) with 544 men (55.7%) and
433 women. Approximately three-quarters of the patients
were hospitalized with HCAP (77.5%), and the remainder
had CAP. The average CURB-65 score, a measure of illness
severity was 2.8 – 1.4 (median 3.0; 25th and 75th percentiles
2.0 and 4.0).
Macrolide-based therapy was administered to 411 pa-
tients (42.1%). Clarithromycin was given to one patient and
azithromycin to 410 patients (99.8%). Patients receiving
macrolide-based therapy were statistically younger, were
more likely to be African-American, had lower CURB-65
and Charlson comorbidity scores, were less likely to have
dementia or be in a bed-bound state, and were less likely to
require hemodialysis than patients who did not receive a
macrolide-based regimen (Table 1). Patients treated with
macrolides were also significantly less likely to be im-
munosuppressed, have had a recent hospitalization, have
been admitted from a nursing home, and have HCAP than
patients not treated with a macrolide. The number of HCAP
risk factors was statistically lower for patients receiving
macrolides (1.3 – 1.2 vs. 2.0 – 1.1; p < 0.001). Hospital
length of stay was significantly shorter for patients receiv-
ing macrolide-based therapy (10.2 – 12.3 d vs. 12.7 – 15.0
d; p = 0.005).
The pathogens associated most commonly with pneu-
monia were methicillin-resistant Staphyloccocus aureus
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(MRSA)(22.7%), S. pneumoniae (19.1%), Pseudomonas
aeruginosa (19.1%), methicillin-sensitive S. aureus (MSSA)
(14.1%), and Haemophilus influenzae (8.0%) (Table 2). Pa-
tients receiving macrolide-based therapy were significantly
more likely to be infected with Legionella spp.,Haemophilus
influenzae, S. pneumoniae, and other Streptococcus species
than patients not receiving a macrolide. Patients not receiving
macrolide-based treatment were more likely to be infected
with Escherichia coli, Klebsiella pneumoniae, MRSA, and
Pseudomonas aeruginosa. Polymicrobial infection occurred
in 139 patients (14.2%) and was less common in patients
treated with macrolides. Secondary bacteremia developed in
336 patients (34.4%) with similar occurrences in patients
treated with and those not receiving a macrolide drug.
The overall hospital mortality rate was 21.1% (n = 206).
The rate was lower among macrolide-treated patients (12.7%
vs. 27.2%; p < 0.001). In-hospital death was associated with
older age, greater CURB-65 and Charlson comorbidity
scores, whereas race, end-stage liver disease, hemodialysis,
immunosuppression, recent hospitalization, admission from
a nursing home, and HCAP (Table 3). The number of HCAP
risk factors was statistically greater among nonsurvivors
(2.0 – 1.2 vs. 1.6 – 1.2; p < 0.001). The hospital length of stay
was similar for nonsurvivors and survivors (12.2 – 19.6 d
vs. 11.5 – 12.1 days; p = 0.495). Kaplan-Meier curve analysis
demonstrated that hospital survival was significantly greater
for macrolide-treated patients (both CAP andHCAP), and the
survival difference was more pronounced for the CAP sub-
group (Fig. 1). There was no difference in survival of the
HCAP patients receiving and not receiving macrolide-based
therapy.
Table 1. Baseline Characteristics of Patients
Macrolide
Treatment
(n = 411)
No Macrolide
Treatment
(n = 566) p value
Age (years – standard
deviation [SD])
58.0– 17.0 62.4 – 16.6 < 0.001
Male (%) 225 (54.7) 319 (56.4) 0.616
Race (%)
White 209 (50.9) 339 (59.9) 0.005
African-American 196 (47.7) 225 (39.8)
Other 6 ( 1.5) 2 ( 0.4)
CURB-65 Score – SDa 2.4 – 1.5 3.1 – 1.3 < 0.001
Charlson Comorbidity
Score – SD
4.7 – 3.4 6.0 – 3.4 < 0.001
Congestive heart
failure (%)
137 (33.3) 195 (34.5) 0.715
Dementia (%) 8 ( 1.9) 36 (16.4) 0.001
COPD (%) 210 (51.1) 302 (53.4) 0.485
End-stage liver
disease (%)
7 ( 1.7) 19 ( 3.4) 0.113
Diabetes mellitus (%) 21 ( 5.1) 46 ( 8.1) 0.065
Bed-bound state (%) 12 ( 2.9) 45 ( 8.0) 0.001
Chronic kidney
disease (%)
55 (13.4) 102 (18.0) 0.051
Hemodialysis (%) 22 ( 5.4) 50 ( 8.8) 0.040
Solid cell tumor (%) 25 ( 6.1) 53 ( 9.4) 0.062
Lymphoma (%) 26 ( 6.3) 41 ( 7.2) 0.575
Leukemia (%) 17 ( 4.1) 26 ( 4.6) 0.731
HIV infection (%) 15 ( 3.6) 9 ( 1.6) 0.040
Other
immunosuppression
(%)
107 (26.0) 207 (36.6) < 0.001
HCAP (%) 266 (64.7) 491 (86.7) < 0.001
Recent
hospitalization (%)
218 (53.0) 422 (74.6) < 0.001
Admitted from a
nursing home (%)
35 ( 8.5) 138 (24.4) < 0.001
Number of HCAP risk factors and
immunosuppression (%)
0 145 (35.3) 75 (13.3) < 0.001
1 90 (21.9) 119 (21.0)
2 104 (25.3) 165 (29.2)
3 62 (15.1) 173 (30.6)
4 10 ( 2.4) 32 ( 5.7)
5 0 2 ( 0.4)
aCURB-65 =Confusion new onset, Urea > 19mg/dL, Respiratory
rate ‡30 breaths/min, Blood pressure <90mmHg systolic or £60mm
Hg diastolic, age ‡ 65 years.
Abbreviations: COPD= chronic obstructive pulmonary disease;
HCAP = healthcare-acquired pneumonia; HIV = human immunode-
ficiency virus.
Table 2. Pathogens Associated with
Pneumonia (No. [%])
Macrolide
Treatment
(n = 411)
No Macrolide
Treatment
(n = 566) P value
Achromobacter spp. 2 ( 0.5) 9 ( 1.6) 0.132
Acinetobacter spp. 9 ( 2.2) 38 ( 6.7) 0.001
Burkholderia spp. 0 1 ( 0.2) 1.000
Citrobacter spp. 0 4 ( 0.7) 0.143
EBSL-producing
Enterobacteriaceae 2 ( 0.5) 5 ( 0.9) 0.705
Enterobacter spp. 6 ( 1.5) 13 ( 2.3) 0.350
Escherichia coli 10 ( 2.4) 43 ( 7.6) < 0.001
Haemophilus
influenzae
46 (11.2) 32 ( 5.7) 0.002
Klebsiella
pneumoniae
12 ( 2.9) 43 ( 7.6) 0.002
Legionella spp. 11 ( 2.7) 1 ( 0.2) 0.001
Moraxella spp. 9 ( 2.2) 11 ( 1.9) 0.788
Morganella spp. 0 4 ( 0.7) 0.143
MRSA 74 (18.0) 148 (26.1) 0.003
MSSA 63 (15.3) 75 (13.3) 0.357
Mycoplasma
pneumoniae
3 ( 0.7) 0 0.074
Proteus spp. 5 ( 1.2) 17 ( 3.0) 0.063
Providencia spp. 0 2 ( 0.4) 0.512
Pseudomonas
aeruginosa
46 (11.2) 141 (24.9) < 0.001
Serratia marcescens 2 ( 0.5) 11 ( 1.9) 0.086
Stenotrophomonas
maltophilia
4 ( 1.0) 10 ( 1.8) 0.416
Streptococcus
pneumoniae
126 (30.7) 61 (10.8) < 0.001
Other Streptococcus
spp.
25 ( 6.1) 15 ( 2.7) 0.008
Polymicrobial
infection
40 ( 9.7) 99 (17.5) 0.001
Positive blood
culture
136 (33.1) 200 (35.3) 0.466
Abbreviations: ESBL= extended-spectrum b-lactamase; MRSA=
methicillin-resistant Staphylococcus aureus; MSSA=methicillin-
sensitive S. aureus.
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A logistic regression analysis adjusted for severity of ill-
ness (CURB-65, Charlson comorbidity score) and potential
confounding factors (congestive heart failure, COPD, de-
mentia, end-stage liver disease, diabetes, solid tumor, lym-
phoma, leukemia, HIV infection, age, gender, recent
hospitalization, admission from a nursing home, immuno-
suppression, and previous antibiotic administration) found
that macrolide use was significantly associated with survival
(AOR 0.63; 95% CI 0.52–0.77; p= 0.021). Similarly, the
propensity score analysis found macrolide use to be signifi-
cantly associated with a lower mortality rate (AOR 0.67; 95%
CI 0.54–0.81; p = 0.043). The overlapping of the propensity
scores for macrolide-treated and non-macrolide-treated pa-
tients within each propensity score quintile reinforced the
validity of the propensity score analysis (Fig. 2). Propensity
score analysis for the subgroup of patients with CAP dem-
onstrated macrolide use to be associated with a lower mor-
tality rate (AOR 0.20; 95% CI 0.11–0.34; p = 0.003);
however, for the subgroup with HCAP, there was no de-
monstrable effect of macrolide treatment on themortality rate
(AOR 0.81; 95% CI 0.65–1.01; p = 0.337).
A logistic regression analysis of the subgroup of patients
receiving macrolide therapy identified only two independent
predictors of a lower mortality rate despite including all
identified co-morbidities and the individual HCAP risks.
Absence of mechanical ventilation (AOR 0.33; 95% CI 0.25–
0.44; p < 0.001) and lower CURB-65 scores (one-point dec-
rements)(AOR 0.52; 95% CI 0.44–0.61; p< 0.001) were in-
dependently associated with a lower mortality rate among
macrolide-treated patients (Hosmer-Lemeshow goodness-of-
fit p = 0.783).
Discussion
We demonstrated that the use of macrolide-based therapy
was associated with a lower risk of in-hospital death among
Table 3. Predictors of In-Hospital Death
Nonsurvivors
(n = 206)
Survivors
(n= 771)
p
value
Age (years – standard
deviation [SD])
64.5 – 15.6 59.5 – 17.1 < 0.001
Male (%) 117 (56.8) 427 (55.4) 0.717
Race (%)
White 132 (64.1) 416 (54.0) 0.013
African-American 71 (34.5) 350 (45.4)
Other 3 ( 1.5) 5 ( 0.6)
CURB-65 Score –SD 3.8 – 0.9 2.6 – 1.5 < 0.001
Charlson comorbidity
score – SD
6.9 – 3.5 5.1 – 3.4 < 0.001
Congestive heart
failure (%)
76 (36.9) 256 (33.2) 0.321
Dementia (%) 13 ( 6.3) 31 ( 4.0) 0.159
COPD (%) 100 (48.5) 412 (53.4) 0.212
End-stage liver
disease (%)
15 ( 7.3) 11 ( 1.4) < 0.001
Diabetes (%) 18 ( 8.7) 49 ( 6.4) 0.229
Bed-bound state (%) 7 ( 3.4) 50 ( 6.5) 0.093
Chronic kidney
disease (%)
43 (20.9) 114 (14.8) 0.035
Hemodialysis (%) 25 (12.1) 47 ( 6.1) 0.003
Solid tumor (%) 19 ( 9.2) 59 ( 7.7) 0.460
Lymphoma (%) 17 ( 8.3) 50 ( 6.5) 0.373
Leukemia (%) 13 ( 6.3) 30 ( 3.9) 0.133
HIV (%) 6 ( 2.9) 18 ( 2.3) 0.634
Other
immunosuppression
(%)
82 (39.8) 232 (30.1) 0.008
HCAP 180 (87.4) 577 (74.8) < 0.001
Recent hospitalization 155 (75.2) 485 (62.9) 0.001
Admitted from
nursing home
47 (22.8) 126 (16.3) 0.031
Number of HCAP risk factors and immunosuppression
0 26 (12.6) 194 (25.2) < 0.001
1 47 (22.8) 162 (21.0)
2 52 (25.2) 217 (28.1)
3 70 (34.0) 165 (21.4)
4 9 ( 4.4) 33 ( 4.2)
5 2 ( 1.0) 0
aCURB-65=Confusion new onset, Urea > 19mg/dL, Respiratory
rate ‡ 30 breaths/min, Blood pressure < 90mm Hg systolic or
£ 60mm Hg diastolic, age ‡ 65 y.
Abbreviations: COPD= chronic obstructive pulmonary disease;
HCAP = healthcare-acquired pneumonia; HIV = human immunode-
ficiency virus.
FIG. 1. Kaplan-Meier curves for patients with communi-
ty-acquired pneumonia (CAP) and healthcare-associated
pneumonia (HCAP) receiving macrolide-based (broken line)
and non-macrolide-based (solid line) regimens.
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consecutive patients admitted to the hospital with pneumo-
nia. However, our sensitivity analysis suggests that this
benefit is seen primarily in patients with CAP, not those with
HCAP. Not surprisingly, the distribution of pathogens in
patients with CAP and HCAP differed, with S. pneumoniae
being the predominant bacterium isolated in patients with
CAP and S. aureus and P. aeruginosa being the most com-
mon bacterial pathogens associated with HCAP. We also
found that among patients treated with macrolides, only
mechanical ventilation and CURB-65 scores predicted the
risk of death.
Previous studies have demonstrated the potential benefit of
macrolide-based therapy in patients with CAP. Asadi et al.
conducted a meta-analysis that included 23 studies and
137,574 patients with CAP [7]. Overall, macrolide use was
associated with a statistically significant mortality reduction
compared with nonmacrolide use. However, there was no
survival advantage, and study heterogeneity was reduced
when analyses were restricted to randomized trials or to pa-
tients treated with guideline-concordant antibiotics (macro-
lide/beta-lactam or respiratory fluoroquinolones). Another
recent meta-analysis reviewed 28 studies of CAP, with the
main objective being to estimate the mortality rate and the
proportion with treatment failure using regimens containing
atypical antibiotic coverage compared with those that had
typical coverage only [9]. There was no difference in the
mortality rates between the atypical-drug arm and the non-
atypical arm. The atypical arm showed an insignificant trend
toward greater clinical success and a significant advantage in
bacterial eradication, which disappeared when evaluating
methodologically high-quality studies alone. Taken together,
these meta-analyses, as well as other clinical studies, suggest
that guideline-based coverage of atypical pathogens in CAP
may be most important in determining clinical outcomes,
including themortality rate and bacterial eradication [7,9,10].
Other investigators have found mixed results with the use
of macrolides in the treatment of community-based respira-
tory infections. Martı´n-Loeches et al. used a propensity score
analysis and found that macrolide-based treatment was not
associated with a better survival rate in critically ill patients
with viral pneumonia attributed to influenza virus H1N1 [11].
However, recent studies in COPD [12], cystic fibrosis
[13,14], bronchiolitis obliterans syndrome [15], and asthma
[16] suggest that macrolides may confer benefit to patients
with community-based respiratory illnesses that are at least
partially attributed to respiratory infections for their path-
ogenesis. In addition to their antimicrobial properties,
macrolides have been believed to benefit patients with in-
flammatory lung diseases, including CAP, through anti-
inflammatory mechanisms. Azithromycin significantly
reduces airway neutrophilia and interleukin-8 mRNA ex-
pression [17]. The anti-inflammatory and immunomodula-
tory activity of macrolides purportedly contribute to their
successful use as therapeutic agents for chronic lung dis-
eases, including cystic fibrosis and diffuse panbronchiolitis
[18].
Recent increasing rates of macrolide resistance in S.
pneumoniae have brought into question the overall utility of
this class of antibiotics for use in CAP [19]. However,
macrolides have antimicrobial activity against P. aerugi-
nosa in eukaryotic media through increased uptake and
reduced efflux of the drug despite high minimum inhibitory
concentrations (MICs) on conventional media (cation-ad-
justed Mueller–Hinton broth) [20]. Despite these observa-
tions, the reported beneficial influence of macrolide therapy
on outcomes in acute pneumonia is still observed primarily
in CAP [7]. The potential antimicrobial influence of mac-
rolides on P. aeruginosa may explain, in part, their efficacy
in patients with cystic fibrosis and other chronic lung dis-
eases [13,14].
Our current study has several major limitations. First, we
restricted our analysis to patients with microbiologically
confirmed bacterial infection. This likely contributed to the
smaller number of patients with CAP compared with HCAP
[21]. We have shown previously that patients with culture-
negative HCAP do as well with traditional CAP treatment as
with treatment targeting HCAP [22]. It is possible that had we
included culture-negative patients in our study, we might
have seen a mortality benefit with macrolide therapy in pa-
tients with HCAP. Moreover, it is possible that some of our
positive cultures from the respiratory tract reflected coloni-
zation rather than true infection. This seems to be a lesser
concern, however, given the adjudication of the radiographic
criteria and the relatively large percentage of patients with
concomitant positive blood cultures. Second, the criteria for
HCAP are somewhat arbitrary and have been disputed as
markers of antibiotic resistance in patients presenting with
pneumonia [23]. Third, we modified our criteria for HCAP
from the 2005 American Thoracic Society/Infectious Disease
Society of America guidelines by including patients with
hospitalization up to one year earlier [24]. This was done
because of the limited number of good-quality studies re-
porting on the relation of timing of prior hospitalization and
antibiotic exposure to subsequent development of antibiotic-
resistant infections and the results of a recent meta-analysis
suggesting that the effects of previous antibiotic prescription
on resistance emergence were conspicuous for as long as
12 mo after exposure [25].
It is important to note that we did not evaluate systemati-
cally for concomitant viral infection. Given the possibility
that some patients with acute viral infections will present
with pneumonia, we may have diluted the influence of
macrolide therapy, especially among patients with HCAP,
given the recent Spanish experience [11]. It also is possible
FIG. 2. Box plots of propensity score quintiles (Q) for
patients with and without macrolide-based therapy.
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that the difference in outcomes associated with macrolide
therapy between patients with CAP and those with HCAP
was attributable to some underdetermined confounding fac-
tor. For example, there were more patients with immuno-
suppression in the HCAP group, which may have influenced
the patients’ response to macrolide therapy. Finally, all
nursing home patients do not appear to be the same. Previous
investigators have shown that among nursing home patients,
prior antibiotic administration and daily living activity are the
best predictors of infection with HCAP pathogens [26]. How-
ever, we captured the presence of a bed-bound state and prior
antibiotic exposure in our analysis, so our assessment of the
nursing home patients should have been complete in this regard.
In conclusion, our data suggest that macrolide therapy is
most effective in patients with CAP, and we could not
demonstrate any influence of these drugs on the survival of
patients with HCAP. This suggests that the use of macrolides
in pneumonia should be based on the published guidelines
that recommend their use when a clinical or epidemiologic
suspicion of infection with atypical pathogens exists, pri-
marily in patients with CAP [3]. The clinical use of risk
factors to identify patients at risk for HCAP may assist cli-
nicians in detecting patients who are unlikely to benefit from
macrolide therapy.
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